Insilico expands Tenacia CNS AI deal to $94.75 million
CURRENT FULL VERSION: Insilico Medicine is expanding its AI-driven CNS partnership with Tenacia Biotechnology in a deal carrying up to $94.75 million in additional potential value, the latest sign that generative AI drug discovery companies are winning repeat business in neurology. The companies said March 26 that they will add a second program aimed at difficult neurological diseases, with Insilico eligible for near-term and milestone payments as the work advances toward a preclinical candidate. (prnewswire.com)
The move builds on an initial collaboration launched in March 2025. That first phase combined Insilico’s Pharma.AI platform and drug discovery capabilities with Tenacia’s scientific expertise and proprietary CNS data, focusing on small-molecule inhibitors designed for strong blood-brain barrier permeability. According to the companies, that program has progressed smoothly enough to justify expansion after roughly a year. (prnewswire.com)
Under the new agreement, the partners will jointly develop an additional candidate with defined properties for the same challenging disease area and push it to the preclinical candidate stage. Insilico framed the second program as a way to explore molecules with distinct profiles against the same target, an approach meant to widen therapeutic options and reduce late-stage development risk. CEO Alex Zhavoronkov said launching a second program with differentiated attributes on the same target in a short time shows the “depth and flexibility” of generative AI in modern drug design. (prnewswire.com)
Tenacia brings a growing neurology footprint to the collaboration. The company has described itself as focused on underserved nervous system disorders, and outside this Insilico deal it has recently been active in Greater China licensing. In March 2026, for example, Tenacia struck a deal with Rapport Therapeutics worth up to $308 million to develop and commercialize RAP-219 for epilepsy and bipolar disorder in Greater China. Earlier, Praxis Precision Medicines partnered with Tenacia on ulixacaltamide for essential tremor, citing Tenacia’s CNS development and commercialization capabilities in China. (fiercebiotech.com)
The broader context is that Insilico has been stacking CNS and inflammation-focused alliances at a steady pace. In February 2026, it announced multiple CNS and autoimmune collaborations with China Medical System, with funding support for at least two programs. Insilico also highlighted an early-2026 CNS collaboration with Hygtia around an NLRP3 inhibitor. Beyond those disease-area-specific deals, the company has also landed a much larger multi-program collaboration with Eli Lilly worth up to about $2.75 billion, including $115 million upfront, to use Pharma.AI across multiple therapeutic areas. Under that agreement, Lilly received exclusive global rights to develop, manufacture, and commercialize select preclinical oral candidates for chosen indications, while the companies also agreed to work on multiple R&D programs around Lilly-selected targets using Insilico’s platform. Taken together, these deals suggest partners are increasingly willing to use AI-native platforms not just for one-off discovery work, but as repeatable engines for pipeline building. That’s an inference based on the pattern of recent collaborations and the fact that several involve shared development responsibilities rather than simple fee-for-service arrangements. (prnewswire.com; pharmashots.com)
Why it matters: For veterinary professionals, especially those tracking neurology, translational medicine, and industry R&D trends, the Tenacia expansion is relevant less for the asset itself than for what it says about the direction of discovery. CNS drug development remains unusually difficult because of disease complexity, biomarker uncertainty, and the challenge of getting molecules across the blood-brain barrier. If AI platforms can reliably generate viable back-up compounds or differentiated candidates earlier in the process, that could eventually influence how neurologic therapies are sourced and de-risked across species, including in companion animal medicine. Insilico’s own public filings note potential applications beyond human therapeutics, including veterinary medicine, even though this deal is firmly human-health focused today. (prnewswire.com)
There’s also a practical business lesson here for animal health watchers: repeat partnering matters. One of the biggest questions around AI drug discovery has been whether early collaborations translate into durable commercial relationships. A second Tenacia program, plus adjacent CNS deals from Insilico and the much larger Lilly alliance spanning multiple therapeutic areas, gives the company another proof point that partners will expand if the first program shows enough traction. That doesn’t guarantee clinical success, but it does indicate that platform credibility is increasingly being judged by follow-on commitments, not just headline deal size. The Lilly structure also underscores how these relationships can mature beyond discovery support into deals that hand big pharma exclusive downstream rights to develop and commercialize AI-originated candidates. (prnewswire.com; pharmashots.com)
What to watch: The next milestones are likely to be target disclosure, nomination of a preclinical candidate from either the first or second Tenacia program, and any future evidence that Insilico or similar AI-discovery firms are applying validated CNS design workflows to comparative or veterinary neurology programs. It will also be worth watching whether future partnerships resemble the Lilly model, with exclusive global rights, milestone-heavy economics, and tiered royalties layered onto AI-enabled discovery work. (prnewswire.com; pharmashots.com)